Experience

Davis Polk is advising Bristol Myers Squibb on its acquisition of Forbius. The transaction includes an upfront payment and future success-based milestone payments. The transaction is…

We advised an ad hoc group of term lenders in connection with the comprehensive recapitalization

Davis Polk is advising Kyocera Corporation in connection with its proposed acquisition of the shares of common stock of AVX Corporation not already owned by Kyocera for $21.75 per share or…

Davis Polk advised an ad hoc group of lenders under Fusion Connect, Inc.’s prepetition secured first-lien credit facility in the chapter 11 restructuring of Fusion Connect, Inc. and certain…

Davis Polk is advising Varagon Capital Partners, L.P. on its agreement to form a new strategic partnership with Aflac Global Investments and the extension of its existing strategic…

Davis Polk advised Crestview Partners on its minority investment in ICM Partners, LLC.Founded in 2004, Crestview is a value-oriented private equity firm focused on the middle market…

Davis Polk is advising Bertelsmann SE & Co. KGaA on its $675 million acquisition of the stake it did not hold in Penguin Random House. Bertelsmann acquired the remaining 25% stake held…

Davis Polk is advising Charles River Laboratories International, Inc. on its approximately $380 million acquisition of HemaCare Corporation. The proposed purchase price equates to $25.40…

Davis Polk advised an ad hoc group of lenders under a $347 million first-lien and a $140 million second-lien term loan credit facility of CTI Foods, LLC …

Davis Polk advised Pernix Therapeutics Holdings, Inc. in connection with the sale of substantially all of its assets to Currax Holdings LLC, an entity formed by affiliates of Highbridge…